«The approval of ipilimumab to treat advanced metastatic melanoma is a game changer not only for the thousands of people fighting this disease, but also for
the entire field of oncology,» says Jill O'Donnell - Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), a nonprofit organization that since 1953 has worked to advance the science of tumor immunology.